Literature DB >> 35138531

Mesenchymal Stem Cells and Selenium Nanoparticles Synergize with Low Dose of Gamma Radiation to Suppress Mammary Gland Carcinogenesis via Regulation of Tumor Microenvironment.

Omayma A R Abozaid1, Laila A Rashed2, Sawsan M El-Sonbaty3, Amira I Abu-Elftouh4, Esraa S A Ahmed5.   

Abstract

Breast cancer is one of the most prevalent and deadliest cancers among women in the world because of its aggressive behavior and inadequate response to conventional therapies. Mesenchymal stem cells (MSCs) combined with green nanomaterials could be an efficient tool in cell cancer therapy. This study examined the curative effects of bone marrow-derived mesenchymal stem cells (BM-MSCs) with selenium nanoparticles (SeNPs) coated with fermented soymilk and a low dose of gamma radiation (LDR) in DMBA-induced mammary gland carcinoma in female rats. DMBA-induced mammary gland carcinoma as marked by an elevation of mRNA level of cancer promoter genes (Serpin and MIF, LOX-1, and COL1A1) and serum level of VEGF, TNF-α, TGF-β, CA15-3, and caspase-3 with the reduction in mRNA level of suppressor gene (FST and ADRP). These deleterious effects were hampered after treatment with BM-MSCs (1 × 106 cells/rat) once and daily administration of SeNPs (20 mg/kg body weight) and exposure once to (0.25 Gy) LDR. Finally, MSCs, SeNPs, and LDR notably modulated the expression of multiple tumor promoters and suppressor genes playing a role in breast cancer induction and suppression.
© 2022. The Author(s).

Entities:  

Keywords:  Breast cancer; Low-dose radiation; Mesenchymal stem cells; Selenium nanoparticles; Tumor microenvironment; Tumor suppressor/promoter genes

Year:  2022        PMID: 35138531     DOI: 10.1007/s12011-022-03146-1

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  56 in total

1.  Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.

Authors:  Peter E Hall; Peter Schmid
Journal:  Expert Opin Emerg Drugs       Date:  2021-04-19       Impact factor: 4.191

2.  Chemotherapy and targeted therapy for breast cancer patients with hepatitis C virus infection.

Authors:  Soha Talima; Hebatallah Kassem; Neemat Kassem
Journal:  Breast Cancer       Date:  2018-09-06       Impact factor: 4.239

Review 3.  Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer.

Authors:  Robert Pirker
Journal:  Curr Opin Oncol       Date:  2020-01       Impact factor: 3.645

Review 4.  Time to rejuvenate ultra-low dose whole-body radiotherapy of cancer.

Authors:  Marek K Janiak; Mateusz Pocięgiel; James S Welsh
Journal:  Crit Rev Oncol Hematol       Date:  2021-03-02       Impact factor: 6.312

5.  Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target.

Authors:  Jing Liu; Jia-Xin Shen; Hua-Tao Wu; Xiao-Li Li; Xiao-Fen Wen; Cai-Wen Du; Guo-Jun Zhang
Journal:  Discov Med       Date:  2018-05       Impact factor: 2.970

Review 6.  Is Ionizing Radiation Harmful at any Exposure? An Echo That Continues to Vibrate.

Authors:  Edouard I Azzam; Nicholas W Colangelo; Jason D Domogauer; Neha Sharma; Sonia M de Toledo
Journal:  Health Phys       Date:  2016-03       Impact factor: 1.316

Review 7.  Low-dose radiation may be a novel approach to enhance the effectiveness of cancer therapeutics.

Authors:  Guozi Yang; Wei Li; Hongyu Jiang; Xinyue Liang; Yuguang Zhao; Dehai Yu; Lei Zhou; Guanjun Wang; Huimin Tian; Fujun Han; Lu Cai; Jiuwei Cui
Journal:  Int J Cancer       Date:  2016-06-28       Impact factor: 7.396

8.  Cancer control related to stimulation of immunity by low-dose radiation.

Authors:  Shu-Zheng Liu
Journal:  Dose Response       Date:  2006-08-28       Impact factor: 2.658

Review 9.  Health Impacts of Low-Dose Ionizing Radiation: Current Scientific Debates and Regulatory Issues.

Authors:  Alexander Vaiserman; Alexander Koliada; Oksana Zabuga; Yehoshua Socol
Journal:  Dose Response       Date:  2018-09-19       Impact factor: 2.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.